Esperion Acquires Corstasis, Bolsters Cardiovascular Portfolio with Nasal Diuretic
Event summary
- Esperion Therapeutics has agreed to acquire Corstasis Therapeutics for $75 million upfront, with up to $180 million in potential milestone payments and royalties.
- The acquisition centers on Enbumyst™, the first FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure, approved in September 2025.
- Esperion will finance the acquisition through existing credit facilities and royalty monetization.
- The deal is expected to close in the second quarter of 2026.
- Corstasis is also advancing a subcutaneous pipeline, including a multidose pen injector.
The big picture
Esperion's acquisition of Corstasis represents a strategic move to expand its cardiovascular franchise and capitalize on the unmet need for rapid-acting diuretics in managing edema associated with heart failure. The $4 billion market opportunity, coupled with Esperion’s existing commercial infrastructure, suggests a significant potential for revenue growth, but hinges on successful integration and regulatory expansion. This acquisition aligns with Esperion’s Vision 2040, signaling a broader commitment to innovation in cardiovascular care.
What we're watching
- Commercial Execution
- Esperion's ability to successfully integrate Enbumyst into its existing commercial infrastructure will be critical to realizing the anticipated revenue growth and justifying the acquisition cost.
- Regulatory Expansion
- The speed at which Esperion can expand Enbumyst’s indications beyond CHF, particularly into hepatic and renal disease, will influence its long-term market penetration.
- Pipeline Progress
- The development and potential commercialization of Corstasis’s subcutaneous pipeline, particularly the multidose pen injector, could unlock additional revenue streams beyond Enbumyst’s current scope.
Related topics